Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Benda Forms JV for HIV Vaccine

publication date: Oct 30, 2007
Benda Pharmaceuticals announced that its majority-owned China subsidiary, SiBiono, has established a joint venture with DNAVEC to develop a therapeutic vaccine for HIV/AIDS. The vaccine uses gene therapy. DNAVEC chose SiBiono for the JV because SiBiono had already received approval in China for another gene therapy, the cancer drug Gendicine®. SiBiono, which has exclusive distribution rights for the HIV vaccine in China, will be responsible for conducting all of the work for approval. More details...

Stock Symbol: (OTCBB: BPMA)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital